Literature DB >> 27579517

Multiple allosteric sites are involved in the modulation of insulin-degrading-enzyme activity by somatostatin.

Grazia R Tundo1,2, Elena Di Muzio3, Chiara Ciaccio1,2, Diego Sbardella1,2, Donato Di Pierro1, Fabio Polticelli3,4, Massimo Coletta1,2, Stefano Marini5,6.   

Abstract

Somatostatin is a cyclic peptide, released in the gastrointestinal system and the central nervous system, where it is involved in the regulation of cognitive and sensory functions, motor activity and sleep. It is a substrate of insulin-degrading enzyme (IDE), as well as a modulator of its activity and expression. In the present study, we have investigated the modulatory role of somatostatin on IDE activity at 37 °C and pH 7.3 for various substrates [i.e. insulin, β-amyloid (Aβ)1-40 and bradykinin], aiming to quantitatively characterize the correlation between the specific features of the substrates and the regulatory mechanism. Functional data indicate that somatostatin, in addition to the catalytic site of IDE (being a substrate), is also able to bind to two additional exosites, which play different roles according to the size of the substrate and its binding mode to the IDE catalytic cleft. In particular, one exosite, which displays high affinity for somatostatin, regulates only the interaction of IDE with larger substrates (such as insulin and Aβ1-40 ) in a differing fashion according to their various modes of binding to the enzyme. A second exosite, which is involved in the regulation of enzymatic processing by IDE of all substrates investigated (including a 10-25 amino acid long amyloid-like peptide, bradykinin and somatostatin itself, which had been studied previously), probably acts through the alteration of an 'open-closed' equilibrium.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  Alzheimer's disease; bradykinin; insulin degrading enzyme; somatostatin; β-amyloid

Mesh:

Substances:

Year:  2016        PMID: 27579517     DOI: 10.1111/febs.13841

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  6 in total

Review 1.  Sleep Disturbance and Alzheimer's Disease: The Glial Connection.

Authors:  Aditya Sunkaria; Supriya Bhardwaj
Journal:  Neurochem Res       Date:  2022-03-18       Impact factor: 3.996

2.  Resveratrol Sustains Insulin-Degrading Enzyme Activity toward Aβ42.

Authors:  Claire A Krasinski; Valerie A Ivancic; Qiuchen Zheng; Donald E Spratt; Noel D Lazo
Journal:  ACS Omega       Date:  2018-10-16

Review 3.  Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease.

Authors:  Namdoo Kim; Hyuck Jin Lee
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

Review 4.  Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Authors:  Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Biomedicines       Date:  2021-01-17

5.  Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.

Authors:  Grazia Raffaella Tundo; Diego Sbardella; Francesco Oddone; Giuseppe Grasso; Stefano Marini; Maria Grazia Atzori; Anna Maria Santoro; Danilo Milardi; Francesco Bellia; Gabriele Macari; Grazia Graziani; Fabio Polticelli; Paolo Cascio; Mariacristina Parravano; Massimo Coletta
Journal:  Biomolecules       Date:  2022-02-16

Review 6.  Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets.

Authors:  Yongle Cai; Jingliu Liu; Bin Wang; Miao Sun; Hao Yang
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.